Results 211 to 220 of about 1,830,783 (287)

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić   +8 more
wiley   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum   +5 more
wiley   +1 more source

Breaking glycolysis: allosteric hotspots for multi-target drug repurposing. [PDF]

open access: yesJ Comput Aided Mol Des
Vural LS   +4 more
europepmc   +1 more source

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said   +13 more
wiley   +1 more source

Therapeutic Target Mapping to Advance Drug Repurposing for Cardiovascular Disease: A Perspective from an Explanted Heart Biobank. [PDF]

open access: yesJ Pers Med
Ng C   +11 more
europepmc   +1 more source

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy